Clovis Oncology Stock Fundamentals
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis Oncology fundamentals help investors to digest information that contributes to Clovis Oncology's financial success or failures. It also enables traders to predict the movement of Clovis Stock. The fundamental analysis module provides a way to measure Clovis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clovis Oncology stock.
Clovis |
Clovis Oncology Company Current Valuation Analysis
Clovis Oncology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Clovis Oncology Current Valuation | 651.32 M |
Most of Clovis Oncology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clovis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Clovis Oncology has a Current Valuation of 651.32 M. This is 95.47% lower than that of the Biotechnology sector and 85.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 96.08% higher than that of the company.
Clovis Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Clovis Oncology's current stock value. Our valuation model uses many indicators to compare Clovis Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clovis Oncology competition to find correlations between indicators driving Clovis Oncology's intrinsic value. More Info.Clovis Oncology is number one stock in return on asset category among related companies. It is number one stock in profit margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Clovis Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Clovis Oncology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Clovis Oncology's earnings, one of the primary drivers of an investment's value.Clovis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clovis Oncology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clovis Oncology could also be used in its relative valuation, which is a method of valuing Clovis Oncology by comparing valuation metrics of similar companies.Clovis Oncology is currently under evaluation in current valuation category among related companies.
Clovis Fundamentals
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 148.76 M | |||
| Gross Profit | 115.3 M | |||
| EBITDA | (224.76 M) | |||
| Net Income | (264.52 M) | |||
| Cash And Equivalents | 94.58 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 436.77 M | |||
| Debt To Equity | 810.00 % | |||
| Current Ratio | 1.17 X | |||
| Book Value Per Share | (2.89) X | |||
| Cash Flow From Operations | (196.06 M) | |||
| Short Ratio | 4.63 X | |||
| Earnings Per Share | (2.08) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 413 | |||
| Beta | 0.22 | |||
| Market Capitalization | 11.77 M | |||
| Total Asset | 472.83 M | |||
| Retained Earnings | (2.3 B) | |||
| Working Capital | 464.12 M | |||
| Current Asset | 539.7 M | |||
| Current Liabilities | 75.58 M | |||
| Z Score | -5.6 | |||
| Net Asset | 472.83 M |
About Clovis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clovis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clovis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clovis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people.
Pair Trading with Clovis Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clovis Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clovis Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Clovis Stock
| 0.78 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.77 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
| 0.65 | GE | GE Aerospace Financial Report 23rd of July 2024 | PairCorr |
| 0.64 | CAT | Caterpillar Earnings Call Today | PairCorr |
| 0.63 | CVX | Chevron Corp Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Clovis Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clovis Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clovis Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clovis Oncology to buy it.
The correlation of Clovis Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clovis Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clovis Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clovis Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stocks Directory Find actively traded stocks across global markets |